


Appendix 1: Results of the interrupted time series analysis

Results of the segmented linear regression, which divides a time series into pre- and post-intervention portions. As the routine infant seven-valent pneumococcal conjugate vaccine programme was introduced in September 2006 with a campaign for those under the age of 2 years, we chose 2006-07 as the intersection between segments (i.e., the intervention). The graph displays the incidence of hospitalisation for all cause pneumonia before and after the introduction of the seven-valent pneumococcal conjugate vaccine, and Table 1 shows the results of the regression analysis. Over the time period there was a general trend for an increase in hospitalisations for pneumonia in children under 5 years of age in both high and low risk groups. In the low risk group the introduction of the seven-valent pneumococcal conjugate vaccine is associated with an immediate and significant reduction in incidence, while such a significant reduction was not observed in the high-risk group. Furthermore, during the post intervention period the incidence in the low risk group did not significantly change while in the high risk group an increase was observed (although also not significant p=0.07)



Appendix 1, Figure 1. Comparison in the incidence trend of hospitalized pneumonia in low-risk and high risk individuals (eligible for the 7-valent pneumococcal conjugate vaccine) before and after the introduction of 7-valent pneumococcal conjugate vaccine.

The expected annual incidence of hospitalisations for non-bacteraemic pneumonia Y_i , is modelled using multiple linear regression. The final model was:

$$Y_i = B_0 + B_1 * T + B_2 * D + B_3 * P$$

Where T is time (in years) since the start of the observation period, D is a dummy variable indicating pre- or post-vaccination period (coded 0 prior to intervention, and

1 otherwise) and P is the time since vaccination, where time prior to vaccination is coded 0.


| Appendix 1 Table 1, showing the outcome of the model for seven-valent pneumococcal conjugate vaccine eligible children (less than 5 years of age) | | | | |
|---|---------------------|-----------------------|---------------------|-----------------|
| | <i>Coefficients</i> | <i>Standard Error</i> | <i>t Statistics</i> | <i>P-value</i> |
| Low risk children (<5 years of age) | | | | |
| Intercept, B ₀ | 240.78 | 11.89 | 20.25 | <0.01 |
| Overall trend <5 years, B ₁ | 9.10 | 2.11 | 4.31 | <0.01 |
| Change in level after vacc, <5 years, B ₂ | -56.81 | 22.43 | -2.53 | 0.03 |
| Difference in trend post- intervention <5 years, B ₃ | -0.41 | 7.62 | -0.05 | 0.96 |
| High risk children (<5 years of age) | | | | |
| Intercept, B ₀ | 221.58 | 19.10 | 11.60 | <0.01 |
| Overall trend <5 years, B ₁ | 18.51 | 3.39 | 5.45 | 0.00 |
| Change in level after vacc, <5 years, B ₂ | -47.95 | 36.04 | -1.33 | 0.22 |
| Difference in trend post- intervention <5 years, B ₃ | 25.68 | 12.24 | 2.10 | 0.07 |

The incidence and case fatality ratio of non-bacteraemic pneumonia are shown in table 2.

| Appendix 1, Table 2, showing the incidence, case fatality ratios of non- bacteraemic pneumonia. | | | |
|---|---------------------------------|----------------------|---|
| Age group | Incidence per 100,000 (2009/10) | Case fatality ratios | Share of pneumococcal non- bacteraemic pneumonia which are 13-valent pneumococcal conjugate vaccine serotypes |
| 2-4 | 270 | 1.5% | Similar to invasive pneumococcal disease see Appendix 2 |
| 5-14 | 62 | 2.6% | Similar to invasive pneumococcal disease see Appendix 2 |
| 15-44 | 218 | 10.8% | Similar to invasive pneumococcal disease see Appendix 2 |
| 45-64 | 744 | 17.8% | Similar to invasive pneumococcal disease see Appendix 2 |
| 65+ | 2883 | 34.1% | Similar to invasive pneumococcal disease see Appendix 2 |

Appendix 2: Poisson regression model to predict the future reduction in VT invasive pneumococcal disease

To predict the future reduction in invasive pneumococcal disease due to vaccine serotypes we fitted Poisson regression models to the corrected number of incident culture confirmed invasive pneumococcal disease cases due to vaccine serotypes for the post seven-valent pneumococcal conjugate vaccine period to the total number of invasive pneumococcal disease cases in yr 0 including PCR positives. We assumed that the number of incident cases is a variable with a Poisson distribution that has a mean depending on the explanatory variable, time (after the introduction of the infant seven-valent pneumococcal conjugate vaccine programme). Numbers of cases were obtained from a recently published study by our group¹ and data regarding the population size were obtained from the Office for National Statistics². The models were estimated using the maximum likelihood method, while exact confidence intervals were calculated using the standard chi-square intervals. We projected the estimates for a maximum of 15 years using the aforementioned Poisson model and projected estimates of the population. Results of the prediction model are displayed in Appendix Figure 1.



Appendix 2, Figure 1. Expected decrease (solid line) and 95% confidence intervals (dashed) in the incidence of invasive pneumococcal disease due to vaccine serotypes after the introduction of the seven-valent pneumococcal conjugate vaccine in England and Wales. Data points represents the number of cases corrected for underlying trends in case ascertainment pre (average 2000-2006) and the post-seven-valent pneumococcal conjugate vaccine vaccination incidence¹.

Appendix 3: Vaccine efficacy

Studies have shown that both antibody responses and opsonic activity in adults are as high or higher after vaccination with the pneumococcal conjugate vaccines than after vaccination with the 23-valent vaccination for the serotypes included in both vaccine formulations³. Also young age could be associated with a more pronounced immune response^{4, 5}. Immunogenicity studies specifically focussing on high-risk individuals such as the frail elderly⁶, HIV-infected^{7, 8}, and transplant recipients^{9, 10} show no significant difference between vaccination with the 23-valent polysaccharide vaccine and the seven-valent pneumococcal conjugate vaccine, although studies focussing on other high-risk individuals e.g. survivors of a pneumococcal pneumonia, and allogeneic stem cell transplant recipients do suggest a (small) advantage of seven-valent pneumococcal conjugate vaccine over 23-valent polysaccharide vaccine^{11, 12}.

However, two clinical trials evaluating vaccine efficacy in high-risk groups show a favourable efficacy estimates for the pneumococcal conjugate vaccines. Both studies looked at HIV-infected individuals, one focussed on adults¹³ while the other focussed on infants¹⁴. The first one included 496 adult Malawi patients, who had recovered from documented invasive pneumococcal disease, of which 88% were HIV-positive. The efficacy of the seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease after 2 doses during the entire follow-up period (median 1.2 years) in HIV-infected adults was estimated at 74% (95% confidence interval [CI], 30-90), but decreased after the first year from 85% to 25%. In contrast a study comparing the 23-valent polysaccharide vaccine with a placebo in HIV infected adults with similar clinical endpoints showed no clinical benefit of the 23-valent polysaccharide vaccine¹⁵. Another study performed in South Africa evaluated the efficacy of 3 doses of the 9-valent conjugated pneumococcal vaccine in both children with and without HIV infection¹⁴. The efficacy against the first episode of invasive pneumococcal disease among HIV-infected infants was 65% (95% CI, 24-86) compared to 83% (95% CI, 39-97) in children without HIV infection. Also in HIV-infected children the efficacy attenuated faster during 5 years of follow-ups 38.8% (95% CI, -7.8-65.2) compared with uninfected children 77.8% (95%CI 34.4-92.5)¹⁶. Furthermore, this trial also evaluated the efficacy against the first episode if radiological confirmed alveolar consolidation (note that this is a measure of all-cause pneumonia, not specific to the pneumococcus). In HIV infected children the point estimate was 13%(95% CI, -7-29), while in non infected children the efficacy was 20%.

In conclusion, immunogenicity data for conjugated pneumococcal vaccines show generally better results than the 23-valent polysaccharide vaccine in non-immunosuppressed adults, while in adults with specific underlying conditions no or only small advantages are observed for the seven-valent pneumococcal conjugate vaccine over the 23-valent polysaccharide vaccine . Nevertheless, a clinical trial showed that conjugated pneumococcal vaccine is effective in HIV-infected adults, while the 23-valent polysaccharide vaccine failed to demonstrate efficacy in a similar study. Also, the nine valent pneumococcal vaccine was shown to be effective in HIV-infected infants, although the vaccine efficacy was lower compared to those without HIV infection. It is however uncertain if these efficacy estimates will also apply for developed countries in which the invasive pneumococcal disease incidence is lower and HAART therapy is generally available³. Furthermore, it should be noted that these studies used multiple doses of the conjugated vaccine.

Appendix 4: Elicitation of vaccine efficacy estimates

We performed a formal elicitation of expert opinions on vaccine related parameters to construct a probability distribution that represent the experts' knowledge and uncertainty. The aim of the elicitation were to estimate efficacy and the level of waning immunity after vaccination with the 13-valent pneumococcal conjugate vaccine in both high-risk immunocompromised and high-risk immunocompetent individuals aged less than 65 years or more than 65 years of age after one (one dose was used in the base case analysis) or two doses of the vaccine

The level of waning immunity was calculated by letting the experts estimate the vaccine efficacy during the first and third year after vaccination. Based on the difference in vaccine efficacy between these years the annual waning rate was calculated assuming an exponential decay of immunity.

A questionnaire covering these areas was designed using an iterative process involving trials on three test subjects and modifications to the questionnaire based on test subject feedback. We recruited five experts of the Pneumococcal Subcommittee of the Joint Committee on Vaccination and Immunisation to undertake the elicitation process, as it is known that there is little additional benefit in combining expert judgments from more than 4 or 5 experts¹⁷. The experts were provided with background information on the question topics, the aims of the study, and the questionnaire by email.

Probability distributions were elicited using the quartile/probability technique, where each expert separately specified their median, lower, and upper quartile estimate¹⁷. After the initial elicitation, distributions were fitted to the estimations and experts were given the opportunity to revise their estimations if they thought this was necessary after comparing their estimate with those of the other experts. Subsequently, the obtained experts distributions were combined mathematically using the method of (linear) opinion pooling. A beta distribution was chosen to fit to the experts' responses as this distribution is defined on the interval (0,1) and therefore suitable for quantifying uncertainty in probabilities. To obtain the distributions we used the Sheffield Elicitation Framework (SHELF, v2.0 www.tonyohagan.co.uk/shelf/).

The result of the elicitation can be found in Table 1 of the main paper for the base-case analysis (after a single dose of the 13 valent pneumococcal conjugated vaccine) and the results after two doses of the 13 valent pneumococcal conjugated vaccine can be found in table 1.


Appendix 4, Table 1. Average vaccine efficacy after two doses of 13-valent pneumococcal conjugate vaccine during the first year of vaccination

| Type of disease | Invasive pneumococcal disease | | | | Non-bacteraemic pneumococcal pneumonia | | | |
|-------------------------------|-------------------------------|-----|-------------------|-----|--|-----|-------------------|-----|
| Immunostatus | Immunocompetent | | Immunocompromised | | Immunocompetent | | Immunocompromised | |
| Age (in years) | 2-65 | ≥65 | 2-65 | ≥65 | 2-65 | ≥65 | 2-65 | ≥65 |
| Vaccine efficacy [§] | 85% | 74% | 68% | 54% | 56% | 46% | 41% | 32% |

[§] Efficacy estimates do not apply for serotype 3 (see method section)¹⁶

Appendix 5: Life expectancy among high-risk groups

The Figure below shows the survival curves for the high-risk immunocompromised population, high-risk immunocompetent, the general population based on the RCGP data collected for the years 2005 to 2010. These data were used to calculate different background life expectancies. The Royal College of General Practitioners (RCGP) data was validated by comparing the calculated survival curves with the survival curve of the general population based on mortality data obtained from the Office for National Statistics (ONS) for the year 2008².



Appendix 5, Figure 1. Survival curves for individuals at different risk of developing invasive pneumococcal disease and the general population. Data taken from Royal College of General Practitioners database and compared with the survival curve for the general population obtained from the Office for National Statistics².

Appendix 6: Used ICD-10 codes to identify possible acute pneumococcal disease

| | |
|-------------|---|
| A40.3 | Septicaemia due to Strep Pneumoniae |
| A40.8 | Other streptococcal septicaemia |
| A40.9 | Strep. Septicaemia non specified |
| A41.9 | Septicaemia, unspecified |
| A49.1 | Streptococcal unspecified |
| A49.9 | Bacterial infection, unspecified |
| B95.3 | Step pneum as the cause of disease classified in other chapters |
| B95.4/B95.5 | Streptococcus as the cause of disease classified in other chapters |
| G00.1 | Pneumococcal meningitis |
| G00.8 | Other bacterial meningitis |
| G00.9 | Bacterial meningitis unspecified |
| G04.2 | Bacterial meningoencephalitis and meningomyelitis not elsewhere classified |
| G04.8 | Other encephalitis, myelitis and encephalomyelitis |
| G04.9 | Encephalitis, myelitis and encephalomyelitis, unspecified |
| G05.0 | Encephalitis, myelitis and encephalomyelitis in bacterial diseases classified elsewhere |
| I33.0 | Acute and subacute infective endocarditis |
| J00 | Acute Nasopharyngitis |
| J01 | Acute sinusitis |
| J02.0 | Acute pharyngitis Streptococcal |
| J02.9 | Acute pharyngitis, unspecified |
| J03.0 | Streptococcal tonsillitis |
| J03.9 | Tonsillitis unspecified |
| J04 | Acute Laryngitis and tracheitis |
| J05 | Acute obstructive laryngitis |
| J06 | Acute upper respiratory infections of multiple and unspecified sites |
| J13 | Pneumonia due to Streptococcus pneumoniae |
| J15.9 | Bacterial pneumonia, unspecified |
| J18 | Pneumonia, organism unspecified |
| J20.2 | Acute Bronchitis due to streptococcus |
| J20.9 | Acute bronchitis, unspecified |
| J21.8 | Acute Bronchiolitis other specified |
| J21.9 | Acute Bronchiolitis, unspecified |
| J22 | Unspecified acute lower respiratory infection |
| J86 | Pyothorax |
| M00.1 | Pneumococcal arthritis and polyarthritis |
| M00.2 | Other streptococcal arthritis and polyarthritis |

Appendix 7: Annual vaccine coverage of 23-valent vaccination

| Appendix 7, table 1. Proportion of patients annually vaccinated by risk groups with the 23 valent pneumococcal polysaccharide as measured in the 2009 data extract from General Practitioners Practices' IT systems. | | | |
|--|------|-------|------|
| Age group (years) | 2-15 | 16-65 | 65 + |
| One or more Risk Group(s) | 4.1% | 1.5% | 7.2% |

Appendix 8: Age group specific incidence of invasive pneumococcal disease

| Appendix 8, table 1. Invasive pneumococcal disease incidence per 100,000 population per risk- and age-group for the epidemiological year 2009-10. | | | | | |
|---|------------|-------|--------|--------|-------|
| Risk type | Age groups | | | | |
| | 2-4y | 5-14y | 15-44y | 45-64y | ≥65y |
| Any risk group | 109.4 | 37.5 | 24.7 | 57.5 | 43.5 |
| splenic dysfunction | 44.2 | 15.2 | 7.4 | 17.2 | 10.8 |
| Chronic Respiratory Disease | 118.8 | 40.8 | 54.5 | 127.1 | 83.0 |
| Chronic Heart Disease | 38.7 | 13.3 | 22.5 | 52.4 | 48.9 |
| Chronic Kidney Disease | 110.1 | 37.8 | 21.2 | 49.5 | 14.0 |
| Chronic Liver Disease | 277.6 | 95.3 | 108.1 | 252.0 | 116.9 |
| Diabetes | 35.5 | 12.2 | 14.9 | 34.7 | 38.0 |
| Immunocompromised | 384.2 | 131.9 | 55.6 | 129.5 | 190.6 |
| HIV Infection | 945.7 | 324.7 | 198.9 | 463.4 | 86.2 |

Appendix 9 Definition of the risk groups in ICD-10 codes

Overview of the used ICD-10 codes to identify risk group. Where possible the lowest specificity was used; e.g. only a letter includes all codes in the corresponding chapter.

| Risk group | Used ICD codes |
|--|---|
| Chronic respiratory disease | J40,J41,J42,J43,J44,J47,J6,J7,J80,J81,J82,J83,J84,Q30,Q31,Q32,Q33Q34,Q35,Q36,Q37 |
| Chronic heart disease | I05,I06,I07,I08,I09,I11,I12,I13,I20,I21,I22,I25,I27,I28,I3,I40,I41,I42,I43,I44,I45,I47,I48,I49,I50,I51,I52,Q2 |
| Chronic kidney disease | N00,N01,N02,N03,N04,N05,N07,N08,N11,N12,N14,N15,N16,N18,N19,N25,Q60,Q61 |
| Chronic liver disease | K70,K71,K72,K73,K74,K75,K76,K77,P78.8,Q44 |
| Diabetes | E10,E11,E12,E13,E14,E24,G59.0,G63.2,G73.0,G99.0,N08.3,O24,P70.0,P70.1,P70.2 |
| Immunosuppression | Malignancies affecting the immune system: C81,C82,C83,C84,C85,C88,C90,C91,C92,C93,C94, C95,C96 HIV: B20,B21,B22,B23,B24 Transplantations: Z94,Z85 (Bone marrow transplants: Z94.8) Conditions affecting the immune system: D56.1,D57.8,D57.0,D57.D61,D70,D71,D72,D73,D76,D80,D81,D82D83,D84, 1,K90.0 |
| Asplenia or dysfunction of the spleen | D73,D56.1,D57.8,D57.0,D57.1,K90.0 |
| Individuals with cochlear implants | Z96.1 |
| Individuals with cerebrospinal fluid leaks | G96.0 |

References

- 1 Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. *Lancet Infect Dis* 2011;11:760-8.
- 2 Office for National Statistics. 2011. www.statistics.gov.uk.
- 3 Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? *Clin Infect Dis* 2011;52:633-40.
- 4 Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009;180:499-505.
- 5 Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. *Clin Infect Dis* 2009;49:1318-25.
- 6 Ridda I, Macintyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, et al. Immunological responses to pneumococcal vaccine in frail older people. *Vaccine* 2009;27:1628-36.
- 7 Feikin DR, Elie CM, Goetz MB, Lennox JL, Carlone GM, Romero-Steiner S, et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. *Vaccine* 2001;20:545-53.
- 8 Lesprit P, Pedrono G, Molina JM, Goujard C, Girard PM, Sarrazin N, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *AIDS* 2007;21:2425-34.
- 9 Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients—three year follow-up of a randomized trial. *Am J Transplant* 2007;7:633-8.
- 10 Kumar D, Chen MH, Wong G, Cobos I, Welsh B, Siegal D, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. *Clin Infect Dis* 2008;47:885-92.

- 11 Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. *Clin Infect Dis* 2007;45:1576-82.
- 12 Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. *J Infect Dis* 2008;198:1019-27.
- 13 French N, Gordon SB, Mwalukomo T, White SA, Mwafuirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. *N Engl J Med* 2010;362:812-22.
- 14 Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *N Engl J Med* 2003;349:1341-8.
- 15 French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. *Lancet* 2000;355:2106-11.
- 16 Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. *Vaccine* 2007;25:2451-7.
- 17 O'Hagen A, Buck C, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson D. Uncertain judgements: eliciting experts' probabilities. Wiley, 2006.
- 18 Andrews N, Kaye P, Slack M, George R, Miller E. Miller Effectiveness of the 13 valent pneumococcal conjugate vaccine against IPD in England and Wales. Available at: <http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf> (page 179) accessed April 2012.). 2012.